# Integra Holdings

> Integra Holdings is a VC fund backing Biotechnology and Pharmaceutical. See 8 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Wallisellen, Switzerland
- Total investments: 8
- Last investment: May 2021
- Lead investor: 75%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/integra-holdings-ltd-/
- Website: http://integra-holdings.com/

Integra Holdings is a unique venture fund that combines academic excellence, funding and R&D guidance together with a strong and proven business network — the most important elements necessary to bring academic innovation to the market. Focusing on an exclusive selection of biotech companies with proprietary solutions and a competitiveadvantage in their respective fields, Integra takes a hands-on approach by providing our portfolio companies the strategic planning and business development necessary to bring their technology to the market.

## Contacts

5 contacts available for Integra Holdings. Shizune tracks 2 team members at Integra Holdings. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/integra-holdings?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 63% |
| Pharmaceutical | 5 | 63% |
| Life Science | 4 | 50% |
| Health Care | 3 | 38% |
| Medical | 2 | 25% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 6 | 75% |
| Series B | 1 | 13% |
| Series F | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Liana Patt | CEO | 0 | https://shizune.co/investors/profile/liana-patt |
| Lior Buchman | Chief Financial Officer | 0 | https://shizune.co/investors/profile/lior-buchman |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Splisense | Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried. | $28.5M | Series B | May 13, 2021 |  |
| BacoCure | BacoCure is developing a novel bacterial product for local therapy of non-muscle invasive bladder cancer (NMIBC) patients. |  | Seed | Jan 01, 2018 |  |
| Rebiotic Rx | Rebiotic Rx is develops novel liposomal antibiotics for antibiotic-resistant bacterial infections. The company develops and produces Rebiotics Rx a PEGylated nano-liposomal formulation of the antibiotic mupirocin. |  | Seed | Jan 01, 2018 |  |
| Atox Bio | Atox Bio is a biotechnology company that specializes in infectious diseases, immunomodulators, and critical care.It focuses on novel modulators of the immune response that target key multiple and interrelated pathways of both the adaptive and innate immune response that play critical roles in infectious and inflammatory diseases as well asischemia/reperfusion injuries.The company was founded in 2003 and headquartered in HaMerkaz, Israel. | $30M | Series F | Dec 04, 2017 |  |
| Nectin Therapeutics | Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. |  | Seed | Jan 01, 2017 |  |
| Splisense | Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTRtranscripts according to the specific mutation carried. |  | Seed | Jan 01, 2016 |  |
| Ophrx | OPhRx is developing novel drug products for topical administration for diseases involving front-of the eye and back of the eye compartments. |  | Seed | Jan 01, 2014 |  |
| NeoProl | NeoProl develops medical formulations designed to the preparation of anesthesia drugs. Its medical formulations offer development of propofol products used for induction and maintenance of anesthesia. The company was founded in 2014 and is headquartered in Jerusalem, Israel. |  | Seed | Jan 01, 2014 |  |

8 of 8 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Adams Street Partners](https://shizune.co/investors/profile/adams-street-partners) — VC Fund, 1 deal together
- [Arix Bioscience](https://shizune.co/investors/profile/arix-bioscience) — VC Fund, 1 deal together
- [Asahi Kasei](https://shizune.co/investors/profile/asahi-kasei) — VC Fund, 1 deal together
- [Biotel](https://shizune.co/investors/profile/biotel) — VC Fund, 1 deal together
- [Israel Biotech Fund](https://shizune.co/investors/profile/israel-biotechfund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [F6 Ventures](https://shizune.co/investors/profile/flat6labs) — VC Fund
- [Oqal](https://shizune.co/investors/profile/oqal) — VC Fund
- [Alesta Yatırım](https://shizune.co/investors/profile/alesta-girisim) — VC Fund

## Featured in investor lists
- [Health Care Investors in Middle East](https://shizune.co/investors/health-care-investors-middle-east)
- [Health Care VC Funds in Middle East](https://shizune.co/investors/health-care-vc-funds-middle-east)
- [Health Care VC Funds in Israel](https://shizune.co/investors/health-care-vc-funds-israel)
- [Biotechnology Investors in Middle East](https://shizune.co/investors/biotechnology-investors-middle-east)
- [Biotechnology VC Funds in Middle East](https://shizune.co/investors/biotechnology-vc-funds-middle-east)
- [Biotech Investors in Middle East](https://shizune.co/investors/biotech-investors-middle-east)

## FAQ

### What does Integra Holdings invest in?

Integra Holdings invests primarily in Biotechnology, Pharmaceutical and Life Science startups, most often at Seed and Series B stage. Most of the 8 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Integra Holdings?

Public channels for Integra Holdings include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Integra Holdings?

The team at Integra Holdings includes Liana Patt (CEO) and Lior Buchman (Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co